Dayleigh Wisener
Family Medicine · Arab, ALNPI 1124710959
Payments from drug & device makers
Across 118 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$261
- AstraZeneca$229
- Bayer$188
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- Lilly USA, LLC$171
- GSK$120
- plus $868 from 21 others
What the payments were for
- Food & beverage$2,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $261 |
| AstraZeneca | 14 | $229 |
| Bayer | 11 | $188 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $188 |
| Lilly USA, LLC | 10 | $171 |
| GSK | 6 | $120 |
| Amgen | 7 | $104 |
| Exact Sciences | 6 | $104 |
| AbbVie | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Novo Nordisk | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Ardelyx, Inc. | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Merck | 2 | $32 |
| Halozyme Inc | 1 | $24 |
| Corcept Therapeutics | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,025 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 19 | $41,260 |
| OzempicSemaglutide | 34 | $35,678 |
| FarxigaDapagliflozin Propanediol | 17 | $14,093 |
| MyrbetriqMirabegron | 13 | $12,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,502 |
| LinzessLinaclotide | 16 | $10,514 |
| EliquisApixaban | 12 | $10,473 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,254 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,501 |
| Omeprazole | 173 | $2,093 |
| Atorvastatin Calcium | 181 | $1,727 |
| Duloxetine Hcl | 70 | $1,407 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,223 |
| Losartan Potassium | 79 | $1,029 |
| Fluticasone Propionate | 66 | $968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $171 | $41,26019 claims |
| Novo NordiskOzempic | $55 | $35,67834 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $120 | $21,75628 claims |
| AstraZenecaFarxiga | $229 | $14,09317 claims |
| AbbVieLinzess | $81 | $10,51416 claims |
| PfizerEliquis | $261 | $10,47312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Arab
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.